Parviz A. Shamlou, PhD | CPhI North America

CPhI North America is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


View, browse and sort the ever-growing list of sessions by pass type, track, and format. With this Session Scheduler, you can build your schedule in advance and access it during the show via export or with the Mobile App, once live. Sessions do fill up and seating is first come, first serve, so arrive early to sessions that you would like to attend.

Parviz A. Shamlou, PhDExecutive Director & HeadJefferson Institute for Bioprocessing

Parviz Shamlou, PhD, is a chemical engineer with nearly 40 years of academic and industry experience in bioprocessing with the focus on biopharmaceutical process development. Dr. Shamlou was most recently the George B. and Joy Rathmann Professor and Director of the Amgen Center for Bioprocessing at Keck Graduate Institute (KGI). During his five-year tenure at KGI, he led the development and implementation of new educational and training programs in bioprocessing that transformed the center’s activities. The core philosophy of these programs was to collaborate with industry to address the growing needs for skilled workforce in biomanufacturing.
During his 40 years of industry and academic work, Dr. Shamlou has served on several scientific committees and boards, been the Editor-in-Chief of the Journal of Biotechnology and Applied Biochemistry, and been a Fellow of the British Institution of Chemical Engineers. He has supervised more than 30 PhD and post-doctoral researchers, and co-authored more than 200 publications in peer-reviewed journals, chapters in books and presentations at national and international conferences and reports. During his industry tenure with Eli Lilly Dr. Shamlou worked on the process development of over a dozen business critical biopharmaceuticals including but not limited to therapeutic proteins, monoclonal antibodies, fusion proteins, and PEGylated proteins.